Dr. Lin Zheng 郑琳
Chief Physician
Department of Minimally Invasive Intervention, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and minimally invasive interventional therapy for solid tumors, including breast cancer and cervical cancer metastases. Procedures include arterial embolization, ablation, stent implantation, and CT-guided biopsy.
Dr. Zheng is a Chief Physician with a medical doctorate and master's supervisor. A visiting scholar at Asan Medical Center in South Korea, Dr. Zheng has led four research projects and received three first-class and one second-class Henan Medical Science and Technology Progress Awards. Publications include five SCI papers.
Professional roles
- Member, Gastrointestinal Professional Committee of the Interventional Group, Radiology Branch, Chinese Medical Association
- Young Member, Tumor Minimally Invasive Therapy Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Minimally Invasive Immunology Committee, National Tumor Minimally Invasive Therapy Industry Technology Innovation Strategic Alliance
- Member, Lung Cancer Professional Committee, Henan Anti-Cancer Association
Name order: in Chinese the family name comes first (Zheng Lin). Papers usually list the name as Lin Zheng or Zheng L.
Selected publications
23 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Cancer Res Ther, 2026 (senior author): Diagnostic accuracy of dual-phase cone-beam computed tomography for celiac arteriography in patients with hepatocellular carcinoma: Comparison with preoperative dynamic contrast-enhanced magnetic resonance imaging. PubMed 42241163
- J Cancer Res Ther, 2023 (senior author): Clinical application of radiofrequency ablation-assisted coaxial trocar biopsies for pulmonary nodules at a high risk of bleeding. PubMed 37675725
- J Vasc Interv Radiol, 2021 (first author): Endovascular Management of Gastric Conduit Hemorrhage following Transthoracic Esophagectomy. PubMed 34022402
- Acta Radiol, 2021 (first author): Percutaneous antegrade removal of foreign bodies in the urinary tract: a 20-year, single-center experience. PubMed 32811158
- J Interv Med, 2021 (first author): Serum midkine levels for the diagnosis and assessment of response to interventional therapy in patients with hepatocellular carcinoma. PubMed 34805946
- Korean J Radiol, 2018 (first author): Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas. PubMed 29520181
- Cardiovasc Intervent Radiol, 2016 (first author): Transcatheter Arterial Embolization for Gastrointestinal Bleeding Secondary to Gastrointestinal Lymphoma. PubMed 27435580
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion